Omeros Corporation (OMER) and Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) Comparison side by side

Omeros Corporation (NASDAQ:OMER) and Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Omeros Corporation 50.06M 15.88 121.05M -2.61 0.00
Crinetics Pharmaceuticals Inc. 2.35M 221.48 30.67M -1.14 0.00

Table 1 highlights Omeros Corporation and Crinetics Pharmaceuticals Inc.’s top-line revenue, earnings per share and valuation.


Table 2 provides Omeros Corporation and Crinetics Pharmaceuticals Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Omeros Corporation -241.81% 174.4% -130.6%
Crinetics Pharmaceuticals Inc. -1,305.11% -38.4% -21.7%


The Current Ratio and Quick Ratio of Omeros Corporation are 2.4 and 2.4 respectively. Its competitor Crinetics Pharmaceuticals Inc.’s Current Ratio is 21 and its Quick Ratio is 21. Crinetics Pharmaceuticals Inc. can pay off short and long-term obligations better than Omeros Corporation.

Analyst Recommendations

Omeros Corporation and Crinetics Pharmaceuticals Inc. Ratings and Recommendations are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Omeros Corporation 0 1 3 2.75
Crinetics Pharmaceuticals Inc. 0 0 1 3.00

The upside potential is 69.75% for Omeros Corporation with average target price of $27.5. Meanwhile, Crinetics Pharmaceuticals Inc.’s average target price is $40, while its potential upside is 85.27%. The information presented earlier suggests that Crinetics Pharmaceuticals Inc. looks more robust than Omeros Corporation as far as analyst view.

Insider and Institutional Ownership

The shares of both Omeros Corporation and Crinetics Pharmaceuticals Inc. are owned by institutional investors at 51.2% and 98.4% respectively. About 6.04% of Omeros Corporation’s share are held by insiders. On the other hand, insiders held about 0.3% of Crinetics Pharmaceuticals Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Omeros Corporation 3.26% 2.87% 45.07% 45.85% -16.23% 70.47%
Crinetics Pharmaceuticals Inc. -3.56% 9.99% 2.73% -6.04% 0% -15.91%

For the past year Omeros Corporation has 70.47% stronger performance while Crinetics Pharmaceuticals Inc. has -15.91% weaker performance.


Crinetics Pharmaceuticals Inc. beats Omeros Corporation on 7 of the 12 factors.

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use during cataract surgery or intraocular lens replacement. Its clinical programs include OMS721 that is in Phase III clinical trial for the treatment of atypical hemolytic uremic syndrome; and in Phase II clinical trial to treat thrombotic microangiopathies, IgA nephropathy, and other renal diseases. The companyÂ’s clinical programs also consists of OMS824, which is in Phase II clinical trial for the treatment of Huntington's diseases and schizophrenia; OMS405 that is in Phase II clinical trial to treat opioid and nicotine addiction; and OMS201, which is in Phase I/II clinical trial for use during urological procedures. Its preclinical programs comprise OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders; OMS906 to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; OMS721 for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; and OMS616 to control surgical and traumatic bleeding. The companyÂ’s preclinical programs also include GPR17 for the treatment of myelin formation; GPR101 for appetite and eating disorders; GPR151 to treat schizophrenia and cognition; GPR161 for triple-negative breast cancer treatment; GPR183 for the treatment of osteoporosis, and Epstein-Barr virus infections and related diseases; GPR174 for modulation of the immune system; and Antibody Platform for metabolic, CV, oncologic, musculoskeletal, and other disorders. In addition, the company is developing OMS103 that has completed Phase III clinical trial for arthroscopic anterior cruciate ligament reconstruction and arthroscopic partial meniscectomy. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.